Long-term therapy with enalapril in patients with nephrotic-range proteinuria.
The effect of enalapril on urinary protein excretion and renal function was studied in six paediatric patients with various renal diseases causing nephroticrange proteinuria. In three younger children (aged 7-9 years) with steroid-resistant nephrotic syndrome, enalapril at a dose of 0.5 mg/kg per day given for 24 months yielded a temporary reduction of proteinuria in one child, a moderate and steady decrease in another and a complete disappearance of proteinuria in the third. Three adolescents, aged 17 years, took enalapril for 24 months at a dose of 20 mg/day. We observed no effect on proteiuria in one patient with Alport syndrome, a complete disappearance of urinary protein in one patient with membranoproliferative glomerulonephritis and a moderate decrease in the third patient who had idiopathic steroid-resistant nephrotic syndrome. Enalapril therapy resulted in an important reduction of proteinuria in two patients and a moderate decrease in three others. However this therapy was accompanied by a fall in glomerular filtration in all subjects, which was very marked in two patients. This fall in glomerular filtration may, however, simply reflect the natural course of the disease.
Proesmans
W
W
Department of Paediatrics, University Hospital, University of Leuven, Belgium.
Wambeke
I V
IV
Dyck
M V
MV
D000293:Adolescent; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002648:Child; D003404:Creatinine / Q000493:pharmacokinetics; D004656:Enalapril / Q000627:therapeutic use*; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D011507:Proteinuria / Q000188:drug therapy*; D012709:Serum Albumin / Q000032:analysis
D000806:Angiotensin-Converting Enzyme Inhibitors; D012709:Serum Albumin; D004656:Enalapril; D003404:Creatinine